Skip Nav Destination
Frontiers of Gastrointestinal Research
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Edited by
S.Karger AG
Volume
34
Status:
Available
ISBN electronic:
978-3-318-05474-3
ISBN print:
978-3-318-05473-6
Book Series:
Frontiers of Gastrointestinal Research
Publication date:
2015
Book Details
The introduction of anti-tumour necrosis factor (TNF) antibodies into the treatment of patients with IBD about fifteen years ago has dramatically improved the quality of life for patients with severe Crohn's disease and ulcerative colitis. But despite the fact this therapeutic approach has been around for quite some time, there has been no comprehensive overview to date. The book at hand aims to amend this shortcoming, presenting for the first time a thorough overview on TNF action, mechanisms of anti-TNF therapy, treatment strategies, side effects, monitoring, biosimilars and related issues. Including state-of-the-art information and research results, this publication will be a valuable source of information and guide clinicians to the optimal treatment decision, improving the quality of life of patients with inflammatory bowel disease. Moreover, rheumatologists or even dermatologists might also find this book of interest.
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Edited by: G. Rogler, T. Hibi, H. Herfarth, O.H. Nielsen
https://doi.org/10.1159/isbn.978-3-318-05474-3
ISBN (print): 978-3-318-05473-6
ISBN (electronic): 978-3-318-05474-3
Publisher: S.Karger AG
Published: 2015
Download citation file:
Digital Version
Pay-Per-View Access
$233.00
Print Version
Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
$233.00
Table of Contents
-
1 - 8: The Effect of TNF-α on the Regulation of Epithelial Function in Inflammatory Bowel DiseaseByKiichiro TsuchiyaKiichiro TsuchiyaDepartment of Advanced Therapeutics for Gastrointestinal Diseases, Graduate School of Tokyo Medical and Dental University, Tokyo, JapanSearch for other works by this author on:
-
9 - 26: Physiological Role of TNF in Mucosal Immunology: Regulation of Macrophage/Dendritic Cell FunctionByAymeric Rivollier;Aymeric RivollieraSection of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Frederiksberg, Denmark;Search for other works by this author on:J. Marsal;J. MarsalbDepartment of Gastroenterology, Skåne University Hospital, Lund, andSearch for other works by this author on:William W. AgaceWilliam W. AgaceaSection of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Frederiksberg, Denmark;cImmunology Section, Lund University, Lund, SwedenSearch for other works by this author on:
-
27 - 34: Physiological Role of TNF in Mucosal Immunology: Regulation of T-Cell FunctionByMichael ScharlMichael ScharlDivision of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, SwitzerlandSearch for other works by this author on:
-
35 - 48: Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Impact on Barrier FunctionByMichael Schumann;Michael SchumannMedizinische Klinik m.S. Gastroenterologie, Rheumatologie und Infektiologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for other works by this author on:Aline KühnelAline KühnelMedizinische Klinik m.S. Gastroenterologie, Rheumatologie und Infektiologie, Campus Benjamin Franklin, Charité - Universitätsmedizin Berlin, Berlin, GermanySearch for other works by this author on:
-
49 - 55: Pathophysiological Role of TNF in Inflammatory Bowel Disease: TNF and Its Effect on Innate Immune DefenseByMichael ScharlMichael ScharlDivision of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, SwitzerlandSearch for other works by this author on:
-
56 - 61: TNF and Its Impact on Adaptive Immune Mechanisms and Chronic InflammationByBritta SiegmundBritta SiegmundMedical Department (Gastroenterology, Infectious Diseases, Rheumatology), Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, GermanySearch for other works by this author on:
-
62 - 72: Binding of Membrane-Bound TNFByRaja Atreya;Raja AtreyaMedical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GermanySearch for other works by this author on:Ulrike Billmeier;Ulrike BillmeierMedical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GermanySearch for other works by this author on:Timo Rath;Timo RathMedical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GermanySearch for other works by this author on:Helmut Neumann;Helmut NeumannMedical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GermanySearch for other works by this author on:Markus F. NeurathMarkus F. NeurathMedical Clinic 1, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, GermanySearch for other works by this author on:
-
73 - 82: Apoptosis of T Cells and MonocytesByTorsten KucharzikTorsten KucharzikDepartment of General Medicine and Gastroenterology, Lüneburg Hospital, University of Hamburg, Hamburg, GermanySearch for other works by this author on:
-
83 - 89: Neutralisation of Soluble Tumor Necrosis FactorByErwin Dreesen;Erwin DreesenLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumSearch for other works by this author on:Ann GilsAnn GilsLaboratory for Therapeutic and Diagnostic Antibodies, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, BelgiumSearch for other works by this author on:
-
90 - 94: Recommended Screening Procedures before Treatment with Anti-TNF AgentsByChristian MaaserChristian MaaserUniversity Teaching Hospital Lüneburg, Department of Gastroenterology Outpatients' Center, Lueneburg, GermanySearch for other works by this author on:
-
95 - 99: The Risk of Formation of Neutralizing AntibodiesByJoshua Clark;Joshua ClarkSection of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Ill., USASearch for other works by this author on:Atsushi SakurabaAtsushi SakurabaSection of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Ill., USASearch for other works by this author on:
-
100 - 103: TNF Antagonist Trough Concentrations and Treatment Efficacy in Inflammatory Bowel DiseaseByNiels Vande CasteeleNiels Vande CasteeleUniversity of Leuven, Therapeutic and Diagnostic Antibodies, Leuven, Belgium and University of California San Diego, Division of Gastroenterology, IBD Center, La Jolla, Ca., USASearch for other works by this author on:
-
104 - 106: What Is a Biosimilar?ByDario NeriDario NeriDepartment of Chemistry and Applied Biosciences, Swiss Federal Institute of Technology (ETH Zurich), Zurich, SwitzerlandSearch for other works by this author on:
-
107 - 112: Is Extrapolation of Safety and Efficacy Data PossibleByMark AinsworthMark AinsworthDepartment of Medical Gastroenterology, Copenhagen University Hospital, Herlev, DenmarkSearch for other works by this author on:
-
113 - 118: Potential Concerns and QuestionsByGerhard RoglerGerhard RoglerDivision of Gastroenterology and Hepatology and Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, SwitzerlandSearch for other works by this author on:
-
119 - 125: Psoriasis-Like Lesions and Skin ReactionsByHans H. Herfarth;Hans H. HerfarthaDepartment of Medicine, Division of Gastroenterology and Hepatology, andSearch for other works by this author on:Millie D. Long;Millie D. LongaDepartment of Medicine, Division of Gastroenterology and Hepatology, andSearch for other works by this author on:Christopher SayedChristopher SayedbDepartment of Dermatology, University of North Carolina, Chapel Hill, N.C., USASearch for other works by this author on:
-
126 - 131: The Elicitation of Rheumatic Symptoms at Vascular SitesByMatthias Geyer;Matthias GeyerJustus-Liebig-University Giessen, Internal Medicine and Rheumatology, Kerckhoff-Klinik, Department of Rheumatology and Clinical Immunology, Bad Nauheim, GermanySearch for other works by this author on:Ulf Müller-LadnerUlf Müller-LadnerJustus-Liebig-University Giessen, Internal Medicine and Rheumatology, Kerckhoff-Klinik, Department of Rheumatology and Clinical Immunology, Bad Nauheim, GermanySearch for other works by this author on:
-
132 - 137: Serum Reaction, Lupus-Like SyndromeByFabian SchnitzlerFabian SchnitzlerDepartment of Medicine II - Grosshadern, Ludwig-Maximilians-University (LMU), Munich, GermanySearch for other works by this author on:
-
138 - 142: Risk of Non-Hematologic Malignancy with Anti-TNF Therapy in Inflammatory Bowel DiseasesByAnimesh Jain;Animesh JainaDepartment of Medicine, Division of Gastroenterology and Hepatology, Johns Hopkins University, Baltimore, Md., andSearch for other works by this author on:Hans H. Herfarth;Hans H. HerfarthbDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, N.C., USASearch for other works by this author on:Millie D. LongMillie D. LongbDepartment of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, N.C., USASearch for other works by this author on:
-
143 - 146: Risk of LymphomaByMasakazu Nagahori;Masakazu NagahoriDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, JapanSearch for other works by this author on:Mamoru WatanabeMamoru WatanabeDepartment of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, JapanSearch for other works by this author on:
-
147 - 151: Risk of Serious InfectionByMakoto NaganumaMakoto NaganumaCenter for Diagnostic and Therapeutic Endoscopy, School of Medicine, Keio University, Tokyo, JapanSearch for other works by this author on:
-
152 - 158: Risk of Post-Operative Infections with Anti-TNF TherapyByBenjamin L. CohenBenjamin L. CohenDr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, N.Y., USASearch for other works by this author on:
-
159 - 163: The ‘Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Crohn's DiseaseByMy-Linh Tran-Minh;My-Linh Tran-MinhService de Gastroentérologie, Hôpital Saint-Louis, APHP, INSERM U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, FranceSearch for other works by this author on:Clotilde Baudry;Clotilde BaudryService de Gastroentérologie, Hôpital Saint-Louis, APHP, INSERM U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, FranceSearch for other works by this author on:Matthieu AllezMatthieu AllezService de Gastroentérologie, Hôpital Saint-Louis, APHP, INSERM U1160, Université Paris Diderot, Sorbonne Paris Cité, Paris, FranceSearch for other works by this author on:
-
164 - 168: Predictor of Treatment ResponseByHiroki Tanaka;Hiroki TanakaIBD Center, Sapporo Kosei General Hospital, Sapporo, Hokkaido, JapanSearch for other works by this author on:Satoshi MotoyaSatoshi MotoyaIBD Center, Sapporo Kosei General Hospital, Sapporo, Hokkaido, JapanSearch for other works by this author on:
-
169 - 177: Step-Up or Top-Down, Combination with Immunosuppression or Not?ByChristiane Barthel;Christiane BarthelDepartment Internal Medicine I, Robert-Bosch-Krankenhaus, Stuttgart, GermanySearch for other works by this author on:Eduard F. StangeEduard F. StangeDepartment Internal Medicine I, Robert-Bosch-Krankenhaus, Stuttgart, GermanySearch for other works by this author on:
-
178 - 184: The ‘Ideal' Anti-TNF Patient: Indications for Anti-TNF Therapy in Ulcerative ColitisByTadakazu HisamatsuTadakazu HisamatsuDivision of Gastroenterology and Hepatology, The Third Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, JapanSearch for other works by this author on:
-
185 - 189: Predictors of the Treatment ResponseByHyo Jong KimHyo Jong KimDivision of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Republic of KoreaSearch for other works by this author on:
-
190 - 194: What Is the Right DosageByPierre MichettiPierre MichettiGastroenterology La Source-Beaulieu and Division of Gastroenterology, CHUV, Lausanne, SwitzerlandSearch for other works by this author on:
-
195 - 200: Fistulizing and Stricturing Crohn's DiseaseByAlain M. SchoepferAlain M. SchoepferDivision of Gastroenterology and Hepatology, Centre Hospitalier Universitaire Vaudois/CHUV, Lausanne, SwitzerlandSearch for other works by this author on:
-
201 - 205: Postoperative Anti-TNF Therapy in the Management of Crohn's DiseaseByArthur Barrie;Arthur BarrieInflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pa., USASearch for other works by this author on:Miguel RegueiroMiguel RegueiroInflammatory Bowel Disease Center and Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, Pa., USASearch for other works by this author on:
-
206 - 213: Anti-TNF-α Therapy for Extraintestinal Manifestations of Inflammatory Bowel DiseaseByOle Haagen Nielsen;Ole Haagen NielsenaDepartment of Gastroenterology, Medical Section, Herlev Hospital, Herlev, andSearch for other works by this author on:Klaus Bendtzen;Klaus BendtzenbInstitute for Inflammation Research, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkSearch for other works by this author on:Jannie PedersenJannie PedersenaDepartment of Gastroenterology, Medical Section, Herlev Hospital, Herlev, andSearch for other works by this author on:
-
214 - 218: Anti-TNF Alpha Agents and BreastfeedingByHythem Al-Sum;Hythem Al-SumDepartment of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai Hospital, University of Toronto, Toronto, CanadaSearch for other works by this author on:Cynthia V. MaxwellCynthia V. MaxwellDepartment of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai Hospital, University of Toronto, Toronto, CanadaSearch for other works by this author on:
-
219 - 223: Anti-TNF Therapy before SurgeryByStephan R. Vavricka;Stephan R. VavrickaaDivision of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, andbDivision of Gastroenterology and Hepatology, Triemlispital Zurich, Zurich, SwitzerlandSearch for other works by this author on:Michael Scharl;Michael ScharlaDivision of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, andSearch for other works by this author on:Gerhard RoglerGerhard RogleraDivision of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, andSearch for other works by this author on:
-
224 - 228: When and How to Stop Anti-TNF Treatment in Inflammatory Bowel Disease: Predictors of Relapse after Stopping TreatmentByEdouard LouisEdouard LouisDepartment of Gastroenterology CHU Liège, and GIGA Research University of Liège, Liège, BelgiumSearch for other works by this author on:
-
229 - 233: Treatment Options after Anti-TNF FailureByTaku KobayashiTaku KobayashiCenter for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Minato-ku, Tokyo, JapanSearch for other works by this author on:
